By Drug Target Review2025-12-08T09:00:32
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2023-11-20T13:43:43
Sponsored by Merck
2024-01-09T09:30:19
Sponsored by Sartorius
2025-09-18T12:00:00
Sponsored by Benchling
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2023-12-11T10:49:07
Sponsored by Leica Microsystems
Site powered by Webvision Cloud